NCT04500821View on ClinicalTrials.gov

Evaluation of the LipiFlow System With a New Activator

NACompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

October 2, 2020

Primary Completion Date

October 30, 2020

Study Completion Date

October 30, 2020

Conditions
Meibomian Gland Dysfunction
Interventions
DEVICE

Activator LFD-2100

LipiFlow treatment with the Activators LFD-2100 will be performed on both eyes with MGD

Trial Locations (3)

76054

Texas Eye Research Center, Hurst

90505

Wolstan & Goldberg Eye Associates, Torrance

93309

Empire Eye and Laser Center, Bakersfield

All Listed Sponsors
lead

Johnson & Johnson Surgical Vision, Inc.

INDUSTRY

NCT04500821 - Evaluation of the LipiFlow System With a New Activator | Biotech Hunter | Biotech Hunter